Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis 

Published byWilliam Long Modified over 5 years ago

Similar presentations

Presentation on theme: "Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis "— Presentation transcript:

1 Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis  Hitomi Koizumi, Tadaaki Yamada, MD, PhD, Shinji Takeuchi, MD, PhD, Takayuki Nakagawa, MS, Kenji Kita, MS, Takahiro Nakamura, PhD, Kunio Matsumoto, PhD, Kenichi Suda, MD, PhD, Tetsuya Mitsudomi, MD, PhD, Seiji Yano, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 7, Pages (July 2012) DOI: /JTO.0b013e a2c Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 17-DMAG suppresses the in vitro growth of EGFR mutant lung cancer cells in the presence of HGF. Tumor cells were continuously treated with increasing concentrations of EGFR-TKI, erlotinib (PC-9, HCC827, Ma-1, Ma-1/Vec, and Ma-1/HGF), CL-387,785 (H1975), or 17-DMAG, with or without HGF (20 ng/ml), and cell growth was determined after 72 hours by MTT assay. Data shown are representative of five independent experiments. Error bars indicate SD of triplicate cultures. EGFR, epidermal growth factor receptor; HGF, hepatocyte growth factor; TKI, tyrosine kinase inhibitor. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a2c) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 17-DMAG suppresses EGF and Met protein expression and phosphorylation even in the presence of HGF. PC-9, Ma-1, Ma-1/Vec, and Ma-1/HGF tumor cells were treated with or without erlotinib (0.3 μmol/l) or 17-DMAG (0.3 μmol/l) for 24 hours, and then stimulated with or without HGF (20 ng/ml) for 10 minutes. The resultant cells were lysed, and the indicated proteins were detected by immunoblotting. EGF, epidermal growth factor; HGF, hepatocyte growth factor. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a2c) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 17-DMAG overcomes HGF-induced erlotinib resistance in vivo. Ma-1/Vec (A) or Ma-1/HGF (B) cells (5 × 106 each) were inoculated subcutaneously into SCID mice on day 0. Mice received oral erlotinib (20 mg/kg/day) or intraperitoneal 17-DMAG (10 mg/kg/day), starting on day 7. Tumor size was measured twice a week and tumor volumes were calculated as described in Materials and Methods. Error bars indicate SEs of six tumors. C, Macroscopic appearances of representative tumors harvested on day 21. *p < 0.01 compared with the control group (Student's t test). 17-DMAG, 17-Dimethylaminoethylamino-17-demethoxygeldanamycin; HGF, hepatocyte growth factor; SCID, severe combined immunodeficiency. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a2c) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 17-DMAG inhibits EGFR and Met expression in vivo. Ma-1/Vec or Ma-1/HGF cells (5 × 106 each) were inoculated subcutaneously into SCID mice on day 0. Mice received oral erlotinib (20 mg/kg/day) or intraperitoneal 17-DMAG (10 mg/kg/day), starting on day 7. Two hours after treatment on day 11, the mice were sacrificed, and their tumors were harvested and examined histologically. Sections were stained with DAPI (nuclear stain), TUNEL (FITC), EGFR (IHC), and Met (IHC), respectively. Bars indicate 50 μm. 17-DMAG, 17-demethoxygeldanamycin; EGF, epidermal growth factor; HGF, hepatocyte growth factor; SCID, severe combined immunodeficiency; DAPI, 4’,6-diamidino-2-phenylindole; TUNEL, terminal deoxynucleotidyl transferase; FITC, fluorescein isothiocyanate; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a2c) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Quantification of apoptotic and proliferative cells, and of angiogenesis in vivo. A, Apoptotic cells, as determined by the TUNEL assay as described in Materials and Methods. B, Tumor-cell proliferation, as determined by the Ki-67-positive proliferation index (percentage of Ki-67-positive cells). C, Microvessel density, as determined by staining with antimouse-CD31 (clone MEC13.3, BD Bioscience) antibody as described in Materials and Methods. Columns, mean of five areas; bars, SD. *p < 0.05 compared with the control group (Student's t test). TUNEL, terminal deoxynucleotidyl transferase. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a2c) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis "

Similar presentations

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy  Flavia.

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy  Flavia.
Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 
Corresponding author:

Corresponding author:
Drug concentration (μM)

Drug concentration (μM)
Molecular Therapy - Oncolytics

Molecular Therapy - Oncolytics
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors
Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy  Mir Alireza Hoda, MD, Amir Mohamed, BSc,

Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy  Mir Alireza Hoda, MD, Amir Mohamed, BSc,
Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,
NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer  Koichi Azuma, MD, PhD, Akihiko Kawahara, PhD, Satoshi.

NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer  Koichi Azuma, MD, PhD, Akihiko Kawahara, PhD, Satoshi.
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis  Dao M Nguyen, MD, Dominique.

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis  Dao M Nguyen, MD, Dominique.
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations 

MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations 
Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC  Manish R.

Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC  Manish R.

Similar presentations

Ads by Google